Severe Autoimmune Hemolytic Anemia Following Rituximab Therapy in a Patient with a Lymphoproliferative Disorder
- 1 January 2003
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 44 (5) , 889-890
- https://doi.org/10.1080/1042819021000055110
Abstract
Rituximab (chimeric anti-CD20 IgG1 monoclonal antibody) is effective in the treatment of relapsed/refractory low-grade lymphomas of B-cell origin as well as in diffuse large B-cell lymphoma. Several reports also demonstrated the efficacy of rituximab for the treatment of autoimmune cytopenia, especially for cold agglutinin disease. We report the first case, to our knowledge, of rituximab-related autoimmune hemolytic anemia. The pathophysiological mechanisms remain unknown, although the drug could act through massive cytokines liberation after destruction of CD20 positive cells by rituximab.Keywords
This publication has 6 references indexed in Scilit:
- Treatment of Waldenström’s Macroglobulinemia With RituximabJournal of Clinical Oncology, 2002
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Rituximab therapy in Waldenstrom's macroglobulinemia: Preliminary evidence of clinical activityAnnals of Oncology, 1999
- Induction of Complete Haematological Remission After Monotherapy with AntLCD20 Monoclonal Antibody (RITUXIMAB) in a Patient with Alkylating Agent Resistant Waldenstrom's MacroglobulinaemiaLeukemia & Lymphoma, 1999
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998
- IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's LymphomaBlood, 1997